He Wang - WuXi Biologics VP Officer
| WXIBF Stock | USD 1.86 0.00 0.00% |
Insider
He Wang is VP Officer of WuXi Biologics
| Phone | 86 510 8183 1205 |
| Web | https://www.wuxibiologics.com |
WuXi Biologics Management Efficiency
The company has return on total asset (ROA) of 0.0551 % which means that it generated a profit of $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.123 %, meaning that it generated $0.123 on every $100 dollars invested by stockholders. WuXi Biologics' management efficiency ratios could be used to measure how well WuXi Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | INSIDER Age | ||
| LLB BA | Alpha Cognition | 72 | |
| Denis Kay | Alpha Cognition | 66 | |
| Qinghai Zhao | Adagene | 63 | |
| MBA MD | Alpha Cognition | 47 | |
| Colleen Johns | Alpha Cognition | N/A | |
| Michael McFadden | Alpha Cognition | 56 | |
| Jc MD | Adagene | 59 | |
| Lauren MBA | Alpha Cognition | N/A | |
| Donald BA | Alpha Cognition | 59 | |
| Fangyong Du | Adagene | 54 | |
| Man MBA | Adagene | 47 | |
| Guizhong Liu | Adagene | 53 | |
Management Performance
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 |
WuXi Biologics Leadership Team
Elected by the shareholders, the WuXi Biologics' board of directors comprises two types of representatives: WuXi Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of WuXi. The board's role is to monitor WuXi Biologics' management team and ensure that shareholders' interests are well served. WuXi Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, WuXi Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| He Wang, VP Officer | ||
| Eileen Wang, IR Senior Director | ||
| Weichang Zhou, Senior Vice President CTO, Executive Director | ||
| Ming Tu, CFO VP | ||
| Li Xiong, VP HR | ||
| Ge Li, Non-Executive Chairman of the Board | ||
| Jijie Gu, Ex Officer | ||
| Zhisheng Chen, CEO, Executive Director | ||
| Cong JD, VP Department | ||
| Tang MBA, Operations, Communications |
WuXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is WuXi Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 4.22 B | |||
| Shares Owned By Insiders | 14.17 % | |||
| Shares Owned By Institutions | 45.95 % | |||
| Price To Earning | 107.74 X | |||
| Price To Book | 5.92 X |
Currently Active Assets on Macroaxis
Other Information on Investing in WuXi Pink Sheet
WuXi Biologics financial ratios help investors to determine whether WuXi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WuXi with respect to the benefits of owning WuXi Biologics security.